Gilead Brings In Sanofi’s Dietmar Berger To Reset Drug Development

The oncology drug development veteran has been hired by former colleague Daniel O’Day as Gilead looks to improve its R&D hit rate.

Gilead
Gilead adds in liver with CymaBay acquisition • Source: Shutterstock: Tada Images

Gilead has poached Sanofi’s Dietmar Berger to be its new chief medical officer and oversee its global development and medical affairs organizations, as it looks to reset after a string of late-stage drug failures.

Berger is currently chief medical officer and global head of development at Paris-based Sanofi, but...

More from Executives On The Move

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.